Antyra Enters into Licensing Agreement for Anticancer Agents From Novo Nordisk A/S

EDISON, N.J.--(BUSINESS WIRE)--Antyra, Inc. today announced that it has entered into a global licensing agreement with Novo Nordisk A/S (NYSE: NVO), for IGF-related antagonists for the treatment of cancer and other diseases. Under the Agreement, ANTYRA will obtain exclusive rights to develop and commercialize certain IGF antagonists discovered during the Research and License Collaboration Agreement entered into between the Companies in December 2001.